News & CommentMalaria

Serious Setback for Patarroyo Vaccine

Science  20 Sep 1996:
Vol. 273, Issue 5282, pp. 1652
DOI: 10.1126/science.273.5282.1652

Summary

A 2-year, $1.5 million trial of a once-promising malaria vaccine called SPf66, created by Colombian biochemist Manuel Patarroyo, has found no evidence that the vaccine is effective in preventing or delaying the disease in children. The results, from a U.S. Army-sponsored trial of SPf66 among more than 1200 children in Thailand from 1993 to 1995, indicate that the vaccine “does not protect against clinical falciparum malaria,” according to a report published in the 14 September issue of The Lancet. Moreover, the authors write that the data are so disappointing that “further efficacy trials are not warranted.”

Related Content